A better delivery system brings anti-inflammatory therapies to critical sites
Arthritis flares — the unpredictable and often sudden worsening of arthritis symptoms — can be debilitating. These episodes can make the management of inflammatory arthritis, which includes rheumatoid arthritis and psoriatic arthritis, challenging for patients and physicians.
But investigators at Harvard-affiliated Brigham and Women’s Hospital (BWH) have found that flares may also represent an important opportunity for improving treatment options.
In experiments carried out in the lab, BWH bioengineers have developed a hydrogel — a soft, flexible material that can be loaded with arthritis drugs and injected locally into an inflamed joint. Instead of delivering the drug continuously at a steady rate, the hydrogel is designed to respond to increased disease activity during flares, releasing the drug when symptoms worsen. The team’s laboratory-based findings are published this week in Nature Communications and investigators are working on next steps to bring their technology closer to the clinic.
“Arthritis represents a huge unmet clinical need,” said co-senior author Jeff Karp,a bioengineer and principal investigator at BWH and Harvard Medical School (HMS) professor of medicine. “Although new therapeutics have been developed, many have had systemic, toxic effects. We wanted to design a delivery system that could be efficient, deliver drugs locally, and release drugs in response to inflammation.”
The newly created flare-responsive hydrogel is made from triglycerol monostearate (TG-18), a compound from the Food and Drug Administration’s list of “generally recognized as safe” compounds. TG-18 is a molecule capable of self-assembling, meaning that it can form a gel-like structure comprising fibers. This structure can be easily injected as a suspension. In this study, the TG-18 hydrogel was loaded with triamcinolone acetonide (TA), used here as a model drug, but could potentially be loaded with many other kinds of anti-inflammatory compounds.
“The hydrogel is designed so that drug release is triggered by the activity of specific, arthritis-related enzymes that are increased during flares. To test the TG-18 hydrogel, we exposed the gel to several different kinds of environments mimicking conditions in arthritic joints,” said Nitin Joshi, co-first author on the work and an instructor of medicine at BWH and HMS.
When the gel was incubated in synovial fluid from a healthy human joint, drug release was minimal, but when incubated in synovial fluid from a patient with rheumatoid arthritis, the drug was readily released from the hydrogel. Importantly, the drug supply was not exhausted in one spike of synovial fluid — instead, it could be released in response to multiple spikes over time. The team also tested the hydrogel’s effects on cells from cartilage and joints, and found that it appeared to be safe.
The team further tested the clinical efficacy of the TG-18 hydrogel in a mouse model of inflammatory arthritis. They chose the K/BxN serum transfer model, in which disease severity can be precisely controlled, which allowed them to test the hydrogel in animals with different degrees of arthritis severity. They found that when arthritis was more severe, the locally injected hydrogel degraded more rapidly, corresponding to increased drug release. Swelling and severity of arthritis diminished in response to the drug-loaded hydrogel.
One of the advantages of the hydrogel is that it offers the promise of treating arthritis specifically in the joints where the disease is flaring, rather than delivering a drug throughout the body.
“Local therapy could be a viable treatment option for patients with only one or a few inflamed joints, said co-corresponding author Joerg Ermann, a rheumatologist in the BWH Division of Rheumatology, Immunology, and Allergy and HMS instructor in medicine. “Moreover, if a patient is already on a systemic drug but is experiencing a flare in a limited number of joints, we could specifically treat these joints rather than switching to systemic therapy or adding another systemic drug. Having this option would substantially increase our ability to successfully manage arthritis flares in the clinic.”
The team will continue testing the hydrogel in preclinical models to further validate it, and continue to advance toward human clinical trials. The technology has been licensed by Alivio Therapeutics, which is developing therapies to treat inflammatory disorders via targeted disease immunomodulation.
Learn more: Treating inflammatory arthritis with hydrogel
The Latest on: Inflammatory arthritis
via Google News
The Latest on: Inflammatory arthritis
- Researchers characterize important regulators of tissue inflammation, fibrosis and regenerationon August 10, 2020 at 12:25 pm
Although macrophages (cells involved in the detection and destruction of bacteria and other harmful organisms as well as dead cells) are classified as immune cells functioning in the activation and ...
- Canine Arthritis Treatment Market Research, Key Players, Trade Segments And Forecast To 2020-2026on August 10, 2020 at 9:52 am
The Canine Arthritis Treatment Market is expected to exceed more than US$ 3.18 Billion by 2024 at a CAGR of 4.4% in the ...
- Small Molecule Therapies for Rheumatoid Arthritis Market Research Report Analysis And Forecasts To 2026on August 10, 2020 at 5:38 am
Market Research Engine has published a new report titled as "Small Molecule Therapies for Rheumatoid Arthritis Market ...
- Arthritis treatment: The two warning signs of the condition similar to COVID-19 symptomson August 7, 2020 at 3:37 pm
There are two warning signs of the condition which share the same symptoms as the deadly coronavirus. Feeling either of these two signs could be an early indication of arthritis.
- 5 Anti-Inflammatory Ingredients to Add to Your Smoothie for a Healthy Booston August 5, 2020 at 7:57 am
Anti-inflammatory smoothies do exist! Instead of blending in boatloads of sugar and artificial ingredients, try these smoothies for inflammation that are stoked with ingredients that may help lower ...
- Rheumatoid arthritis linked to a lower risk of type 2 diabeteson August 5, 2020 at 12:20 am
A recent analysis of a US commercial insurance database found that adults with rheumatoid arthritis had a lower risk of developing type 2 diabetes than other individuals, including those with other ...
- Study: Anti-inflammatory drug may be first to slow arthritison August 3, 2020 at 10:29 pm
There are currently no medications that can slow down the common form of arthritis that strikes aging knees and hips. But a study suggests a powerful, and expensive, anti-inflammatory drug could ...
- Could the First Drug That Slows Arthritis Be Here?on August 3, 2020 at 2:45 pm
There are currently no medications that can slow down the common form of arthritis that strikes aging knees and hips. But a new study suggests a powerful, and expensive, anti-inflammatory drug could ...
- Novel cell may warn of rheumatoid arthritis flare-upon August 3, 2020 at 7:37 am
According to the study authors, if doctors can reliably identify these new cells in patients, they may be able to warn them about an approaching flare-up.
via Bing News